PHARMACEUTICAL COMPOSITIONS, INCLUDING ATTM, AND METHODS TO ACHIEVE AND MAINTAIN A TARGETED AND STABLE COPPER STATUS AND PREVENT AND TREAT COPPER-RELATED CENTRAL NERVOUS SYSTEM DISEASES

摘要

Pharmaceutical compositions include a sustained release formulation of an agent that induces copper malabsorption in an animal or human. The pharmaceutical compositions preferably include ammonium tetrathromolybdate (ATTM) formulations having targeted particle sizes, preferably in the 150-700 micron range.